T. Mason

发表

Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.

E. Barrett-Connor, K. Ensrud, K. Krueger, 2003, Clinical therapeutics.

The effect of chronic insulin delivery via the intraperitoneal versus the subcutaneous route on hepatic triglyceride secretion rate in streptozotocin diabetic rats.

M. Prentki, A. Giacca, G. Steiner, 2002, Atherosclerosis.

The effect of insulin delivery route on hepatic lipid and glucose metabolism in streptozotocin-diabetic rats

T. Mason, 1998 .

Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.

B. Bengtsson, G. Johannsson, I. Pávó, 2002, The Journal of clinical endocrinology and metabolism.

Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats.

G. Lewis, A. Giacca, V. Tchipashvili, 1999, Diabetes.

The role of factors that regulate the synthesis and secretion of very-low-density lipoprotein by hepatocytes.

T. Mason, Timothy M. Mason, 1998, Critical reviews in clinical laboratory sciences.

Chronic intraperitoneal insulin delivery, as compared with subcutaneous delivery, improves hepatic glucose metabolism in streptozotocin diabetic rats.

A. Giacca, T. Mason, G. van de Werve, 2000, Metabolism: clinical and experimental.

Lipid-induced β-cell dysfunction in vivo in models of progressive β-cell failure

A. Mari, G. Lewis, A. Giacca, 2007 .

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

P. Neven, L. Plouffe, C. Arnaud, 2003, Menopause.

Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure.

A. Mari, G. Lewis, A. Giacca, 2007, American journal of physiology. Endocrinology and metabolism.